Table 2.
Neoadjuvant immunotherapy trials currently registered with clinicaltrials.gov.
| NCT Number | Acronym | Study Status | Drug(s) | Resectability | Operative Goal |
|---|---|---|---|---|---|
| NCT05471674 | Completed | Nivolumab | Potentially Resectable | Resection | |
| NCT04224480 | Recruiting | Pembrolizumab | Resectable | Resection | |
| NCT03337841 | Unknown | Pembrolizumab | Resectable | Resection | |
| NCT05440864 | NEOTOMA | Not Yet Recruiting | Durvalumab + Tremelimumab | Resectable | Resection |
| NCT03682276 | PRIME-HCC | Ipilimumab + Nivolumab | Resectable | Resection | |
| NCT03510871 | Unknown | Ipilimumab + Nivolumab | Resection | ||
| NCT04658147 | Recruiting | Nivolumab + Relatlimab (LAG3) | Potentially Resectable | Resection | |
| NCT04123379 | Active, Not Recruiting | Nivolumab + BMS-813160, BMS 986253 (CCR2/5) | Resectable | Resection |